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Objectives: We aimed to explore the association between vitamin D levels and the severity, mortality and
microbiological etiology of community-acquired pneumonia.
Methods: Vitamin D levels (both, the reservoir form 25-OH and the activated form 1,25-OH2) of 300 randomly
selected patients with community-acquired pneumonia due to pre-specified pathogens included in the German
competence network (CAPNETZ) study were measured. Prior to statistical analysis, values of 25-OH and 1,25-OH2
were power-transformed to achieve parametric distribution. All further analyses were performed with seasonally
and age adjusted values.
Results: There was only a modest (Spearman Coefficient 0.38) positive correlation between 25-OH and 1,25-OH2.
For 1,25-OH2 but not 25-OH, the general linear model revealed a significant inverse correlation between serum
concentration and CURB score (p = 0.011). Liver and respiratory co-morbidity were associated with significantly
lower 25-OH values and renal co-morbidity with significantly lower 1,25-OH2 values. No significant differences of
1,25-OH2 or 25-OH between different pathogens (influenza virus, Legionella spp., Streptococcus pneumoniae) were
detected.
Conclusion: For 1,25-OH2, we found a significant and independent (controlled for age, season and pathogen)
negative correlation to pneumonia severity. Therefore, supplementation of non-activated vitamin D to protect from
pneumonia may be non-sufficient in patients that have a decreased capacity to hydroxylate 25-OH to 1,25-OH2.
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There is growing evidence that the effects of vitamin D
reach far beyond calcium and bone metabolism. In re-
cent years several immune modulatory effects of vitamin
D have been described.
Biological activation of vitamin D requires a stepwise
hydroxylation to first vitamin D 25-OH by the 25-hy-
droxylase (CYP27A1) in the liver. The second hydro-
xylation is catalyzed by 1α-hydroxylase (CYP27B1) in
the kidney and reveals finally the biologically active form* Correspondence: mathias.pletz@med.uni-jena.de
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unless otherwise stated.of vitamin D: vitamin D 1,25-OH2. Whereas 1,25-OH2
exhibits a short half live of 4-6 h, the much less active
precursor 25-OH can be considered as a reservoir with a
substantially increased half live of 3 weeks. Recently, it
has been recognized that besides the kidney, leukocytes
contain 1α-hydroxylase and can therefore activate
25-OH [1].
No common definition exists for adequate vitamin D
status measured as 25-OH serum concentrations. A
recent guideline has been suggested that vitamin D defi-
ciency be defined as 25-OH below 20 ng/ml, insuffi-
ciency as 21–29 ng/ml, and sufficiency as 30–100 ng/ml
[2]. According to this guideline, serum 1,25-OH2 does
not reflect vitamin D reserves and is frequently eitherd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ciency [2].
There is an increasing number of in vitro, ex vivo and
animal studies describing the effects of Vitamin D on
the innate immune response as well as on the B and T
cell response with sometimes contradictory results (for
review see [3].
In summary, 1,25-OH2 seems to facilitate direct anti-
microbial effects of the innate immune system and to
attenuate an (over-)whelming inflammatory response by
modulating the crosstalk between cells of the innate im-
mune system and T cells.
Prospective studies investigating a possible protective
effect of vitamin D alimentation against respiratory in-
fections revealed also conflicting results [4]. In fact,
there are only 2 high quality vitamin D alimentation
studies that showed an improvement of a clinically rele-
vant endpoint: An randomized controlled trial (RCT) by
Nursyam et al. found an increased sputum conversion
rate in 67 Indonesian adult patients with tuberculosis [5]
and Urashima et al. reported a significant reduction of
Influenza A infections (relative risk 0.58; 95% CI 0.34,
0.99) in 187 Japanese children [6]. Recently, a systematic
review on 39 studies addressing the value of vitamin D
on prevention of respiratory tract infections (4 cross-
sectional studies, 8 case–control studies, 13 cohort
studies and 14 clinical trials) satisfying review eligibility
criteria was published. According to the authors, results
from RCTs were conflicting and they suggested to con-
duct studies in populations with a high prevalence of
vitamin D deficiency at baseline, using doses sufficient
to induce sustained elevation of serum 25-OH to detect
an effect [4]. All these studies used vitamin D and none
of its metabolites for supplementation.
Our study aimed to identify associations between
disease severity and/or specific respiratory pathogens in
community-acquired pneumonia (CAP) and the levels of
vitamin D reservoir form 25-OH and its active form,
1,25-OH2. In contrast to other studies, that assessed
only D 25-OH (the vitamin D “reservoir”); we measured
the serum concentration of both, 25-OH and 1,25-OH2
(the “active” metabolite) and we used transformed values
to control for the impact of age and season.
Methods
Design and patient population
This was a cross sectional study analysing vitamin D levels
of 300 randomly selected patients enrolled into the large
prospective CAPNETZ cohort study. The inclusion cri-
teria for the CAPNETZ study were age > =18 years, the
presence of a new infiltrate on chest radiography, and
at least 1 of the following criteria: history of fever
(temperature > =38.3°C), cough, production of purulent
sputum, or focal chest signs on auscultation. Patients whohad been hospitalized during the 28 days preceding the
study patients with severe immunosuppression or active
tuberculosis were excluded. The study was approved by
the ethical review board of each participating clinical
centre, and all patients included gave informed consent.
Detailed information on CAPNETZ methodology is pro-
vided elsewhere [7]. Follow up by a phone call (patient or
next of kind or family physician) was conducted 30 +/- 2
days and 180 days after enrolment.
Sample selection
Samples of patients with confirmed pneumococcal pneu-
monia (n = 100), confirmed influenza pneumonia (n = 50),
confirmed legionella pneumonia (n = 49), and without any
pathogen detected (n = 101) were randomly selected by
using the random sample selection function of SPSS 20.0.
Samples were derived from patients due to selected
respiratory pathogens supposed to induce different im-
munological responses. All samples were taken at the time
of CAP-diagnosis.
Data collection
In this prospective cohort study, all demographic, clinical
and diagnostic data of the patients were recorded using
standardized web-based data acquisition. The study period
comprised 79 months starting on 1st June 2002 and en-
ding 31st December 2008.
Pneumococcal vaccination status was considered posi-
tive, if patients had received pneumococcal vaccine within
the last 5 years prior enrolment.
Processing of samples
All available respiratory specimens and blood cultures
were immediately processed in the local microbiology
laboratories of the participating clinical centers. Gram
staining and culture were performed for all respiratory
samples. Undiluted PBS and BAL fluid samples were
also cultured on charcoal-yeast extract agar if Legionella
spp. was suspected. Urine was tested for the presence of
S. pneumoniae and Legionella spp. antigens using the
Binax Now test and Legionella Now test (Binax Inc), re-
spectively. Virus identification and further subtyping was
carried out as described previously [8].
25-OH was measured in serums samples obtained at
enrolment by the LIAISON® 25 OH Vitamin D TOTAL
chemiluminescent immunoassay from DiaSorin, Germany
according to the manufacturer`s protocol. 1,25-OH was
measured in serums samples obtained at enrolment by the
1,25-Dihydroxy Vitamin D EIA kit from IDS, Germany ac-
cording to the manufacturer`s protocol. This is a complete
assay system for the purification of 1,25-OH2 in human
serum by immunoextraction followed by quantitation by
enzyme immunoassay.
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S. pneumoniae was considered as pathogen when (i) iso-
lated from blood cultures or pleural fluid cultures or (ii) in
the presence of a good quality sputum revealing > 25 poly-
morphonuclear cells and < 10 epithelial cells per power
field (total magnification × 100) and predominant growth
in culture of sputum (≥106 cfu) or BAL (≥ 104 cfu/mL) or
(iii) when the antigen was detected in urine.
The diagnosis of Legionella pneumonia was considered
definite if the patient met one of the following criteria:
(1) isolation of Legionella species from the culture of a
respiratory sample; (2) detection by PCR; or (3) detec-
tion by urinary antigen testing.
Patients with PCR - positive influenza respiratory sam-
ples without a secondary bacterial or viral pathogen de-
tected were defined as influenza pneumonia, therefore
bacterial superinfections were excluded.
Vitamin D deficiency was defined as a D 25-OH below
20 ng/ml, insufficiency as 21–29 ng/ml, and sufficiency
as 30–100 ng/ml [2]. For D 1,25-OH2 deficiency, there
is no established cut off [2]
Statistics
Prior to statistical analysis data of 25-OH and 1,25-OH2
were power-transformed to achieve parametric distribu-
tion. Due to the well-known seasonal variation, we first
examined the influence of the month of blood sample
date on vitamin D levels. All further analyses have been
performed with seasonally adjusted (monthly mean)
values of both, 25-OH and 1,25-OH2.
Influence of possible confounders like age, duration of
respiratory symptoms until blood drawing, presence of
renal comorbidity, pneumonia severity (CURB) and in-
flammation markers have been tested by general linear
models (GLM). For age as a general confounder was ad-
justed as well in all subsequent models.
In a final step, 25-OH and 1,25-OH2 levels in the
subgroups formed by the pathogens were compared by
means of general linear models with pathogen as factor.
P-values (p) and respective test statistics (degrees of
freedom, Fx,y) are displayed.
There was only one single case of missing data for
Vitamin D values. This one was handled as such and not
replaced by estimates. Patients with missing data in the
covariates were excluded from the respective analysis.




Patients’ characteristics and comparison between the
four groups (no pathogen detected, influenza, legionella
and S.pneumoniae) are displayed in Table 1. Except for
hepatic co-morbidities (highest proportion in patientswith pneumococcal pneumonia), sex (high proportion of
males in patients with legionella) and D 25-OH (lowest
transformed values in patients with influenza) and CRP
levels (lowest values in patients with influenza), there
were no statistically significant differences. Considering
the non-transformed values of 25-OH, 82% of the cohort
exhibited vitamin D deficiency.Correlation of 25-OH and 1,25-OH2 serum concentrations
There was a modest positive correlation between 25-0H
and 1,25-OH2 (Spearman Correlation Coefficient 0.38,
p <0.0001; Figure 1). We found no relationship with
CRP, neither for Vitamin D 25-OH nor for Vitamin
D1,25-OH2.Impact of age and season
The well-known seasonal pattern of vitamin D metabo-
lites was confirmed for 25-OH but not for 1,25-OH2
(F11,287 = 5.13, p < 0.001 and F11, 287 = 1.4, p = 0.172, re-
spectively, based on power-transformed values; Figure 2).
After seasonal adjustment, age had a significant impact
on 1,25-OH2 levels (F1,297 = 6.06, p = 0.0144) but not on
25-OH levels (F1,297 = 0.03, p = 0.8588).
To control for the impact of season and age, all further
analyses were performed based on seasonally and age
adjusted D 25-OH and D3 1-25-OH2 values.Impact of pathogen
After adjustment for age and season, no significant dif-
ferences between the four groups (pneumonia with no
pathogen detected, pneumococcal pneumonia, legionella
pneumonia, influenza pneumonia, Table 1) were detected.
Surprisingly, there was a significant difference within the
influenza group: When we separately analyzed influenza A
(n = 36) and B (n = 14), we found equal to lower values for
25-OH in Influenza A compared to influenza B (10.8 ± 7.7
vs. 12.7 ± 13.8, F1,48 = 0.20, p = 0.6595) but significantly
higher values for 1,25-OH2 in influenza A compared to in-
fluenza B (63.5 ± 38.3 vs 31.4 ± 24.1, F1,48 = 8.05, p = 0.0067).Impact of comorbidity
There was a general trend towards lower 25-OH and
1,25-OH2 values in presence of any co-morbidity (Table 2).
However, only three associations revealed statistical sig-
nificance: Liver disease was associated with significantly
lower D 25-OH values (8.9 vs. 14.1 ng/ml, F1,295 = 4,84,
p = 0.0285), respiratory disease was associated with sig-
nificant lower D 25-OH levels (12.6 vs. 14.6 ng/ml,
F1,290 = 4.70, p = 0.031) and renal co-morbidity was asso-
ciated with lower D 1,25-OH2 values (34.1 vs. 50.2 pg/ml,
F1,295 = 10.63, p = 0.0012).
Table 1 Patient’s characteristics
Parameter No pathogen






pneumonia (n = 100)
ANOVA resp.
Fishers exact test
n n n n Test statistic p value
Age (mean, SD) 59.43 15.9 60.13 17.8 62.65 16.7 57.41 17.0 F3,296 = 1.12 0.3403
Sex (male % n)* 61.4% 62 52.0% 26 71.4% 35 49.0% 49 0.0437
Active smoker 40.6% 41 38.0% 19 36.7% 18 43.0% 43 0.8855
Heart insufficiency 11.9% 12 12.0% 6 20.4% 10 11.1% 11 0.4435
Cerebrovascular co-morbidity 5.1% 5 10.0% 5 2.0% 1 7.0% 7 0.3649
Diabetes mellitus 13.9% 14 10.0% 5 22.4% 11 13.0% 13 0.3454
Respiratory co-morbidity 33.0% 33 30.0% 15 38.8% 19 32.0% 32 0.8059
Hepatic co-morbidity* 0.0% 0 2.0% 1 6.1% 3 7.0% 7 0.0167
Renal co-morbidity 5.0% 5 6.0% 3 12.2% 6 6.0% 6 0.4034
Vaccination with the 23 PPV 14.3% 14 10.0% 5 14.3% 7 6.1% 6 0.1158
Vaccination with the TIV 38.4% 38 32.0% 16 37.5% 18 23.5% 23
From nursing home 3.0% 3 2.0% 1 0.0% 0 4.0% 4
CURB-index 0.2829
0 56.0% 42 50.0% 21 55.6% 20 38.7% 29
1 32.0% 24 38.1% 16 33.3% 12 52.0% 39
2 10.7% 8 11.9% 5 8.3% 3 9.3% 7
3 1.3% 1 0.0% 0 2.8% 1 0.0% 0
Hospitalization 58.2% 57 65.3% 32 75.5% 37 71.1% 69 0.1259
180 day mortality 7.1% 7 4.1% 2 6.4% 3 1.0% 1 0.1154
30 day mortality 1.0% 1 2.1% 1 2.1% 1 0.0% 0
Deficient/insufficient/sufficient 74.3/16.8/8.9% 75/17/9 92.0/2.0/6.0% 46/1/3 77.6/22.4/0% 38/11/0 82.3/12.7/5.0% 87/9/3
D3 25 OH [ng/ml] (mean ± SD)** 16.2 ± 9.0 11.3 ± 9.7 14.1 ± 7.1 12.9 ± 7.4 F3,295 = 6.66 0.0002
D3 1,25 OH2 [pg/ml] (mean ± SD)*** 51.5 ± 24.6 54.5 ± 37.6 52.4 ± 38.4 42.4 ± 23.0 F3,295 = 2.43 0.0651
CRP [mg/l] (mean ± SD)* 105.2 ± 108.7 65.1 ± 70.1 136.2 ± 142.7 192.7 ± 150.3 F3,274 = 10.69 <0.0001
All values are displayed as percentage and absolute number within the columns if not stated otherwise.
All differences did not reach statistically significance except *.
**ANOVA was conducted using the transformed D 25-OH and D3 1,25-OH values, respectively.












Figure 1 Correlation between 25-OH and 1,25-OH2 blood levels (raw data).
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Because of the impact of age on 25-OH and 1,25-OH2
serum concentrations, we used the CURB instead of the
CRB-65 score to investigate the association between ini-
tial severity of pneumonia and vitamin D. For 1,25-OH2
but not 25-OH, we found a significantly negative cor-
relation with increasing CURB-score values. The general
linear model revealed a significant association between
low 1,25-OH2 serum concentration and high CURB
scores (p = 0.011), whereas there was no significant asso-
ciation between 25-OH and CURB (p = 0.325).
Both, 25-OH and 1,25-OH2 were lower for patients who
needed to be hospitalized: 12.8 ± 7.8 vs. 16.2 ± 10.0 ng/ml
and 44.3 ± 28.2 vs. 58.2 ± 30.0 pg/ml, respectively.
We also found a significant impact of 25-OH and
1,25-OH2 serum concentrations -all samples were taken
on admission- on duration of hospitalization. Lower levels
were associated with longer hospitalization (F1,290 = 17.69
p < 0.001 and F1,290 = 46.16, p < 0.001, respectively).
There was no significant impact of neither 25-OH nor
1,25-OH2 serum concentrations on fatal outcome (Chi21 =
0.2374, p = 0.6261 and Chi21 = 0.1964, p = 0.6576 respec-
tively). However, the number of deaths in this cohort was
limited (n = 13). Since only 2 patients received mechanical
ventilation, we did not analyse the impact on respiratory
failure.Discussion
We found that 1,25OH2 serum concentration is inversely
correlated with severity of CAP in means of the CURBscore without any significant association to specific
pathogens.
However, CURB score has been evaluated as predictor
of mortality and is therefore only a surrogate parameter
for severity. Admission to ICU as parameter for severity
could not be accessed due to a large amount of missing
data. Another limitation of our study is the lack of a
healthy control group. Regarding ethnicity and geogra-
phical latitude, our cohort is comparable to the subgroup
of non-Hispanic whites analyzed within the US- National
Health and Nutrition Examination Survey (http://www.
cdc.gov/nutritionreport/99-02/pdf/nr_ch2b.pdf). In this
survey, approximately 10 percent of the general popula-
tion had 25-OH concentrations < 11 ng/ml. In our cohort,
45.4% of the patients had 25-OH values of less than
11 ng/ml. The geometric mean of 25-OH for (not acutely
ill) non-Hispanic whites in this survey was 21.6 ng/mL for
adults between 20–59 years and 21.0 ng/mL for adults
over 59 years, which is markedly higher than the values
measured in our pneumonia cohort.
As others, we found a high variability of vitamin D me-
tabolites with season and age accounting for the majority
of the observed variances. Therefore, we decided to use a
model controlling for the influence of season and age in-
stead of sequential univariate-multivariate testing because
it is well-known that these 2 factors have a substantial in-
fluence on vitamin D levels [9]. We did not detect signifi-
cantly different transformed 1,25-OH2 and 25-OH levels
between different respiratory pathogens, that probably
provoke different pathways of the innate immune system.
However, if we applied the cut off values for “deficiency”,
Figure 2 25-OH (A) and 1,25-OH2 (B) blood levels by season (raw data).
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data, we found that the proportion of deficient patients
was highest in the group of influenza pneumonia and lo-
west in the group of legionella pneumonia. This is likely
to be explained by the fact that incidence of influenza and
pneumococcal but not of legionella infections is increased
during winter season.
The interpretation of the observed difference within
the influenza group between influenza A and B is dif-
ficult. Because vitamin D skews the immune system to-
wards a more tolerogenic state, some authors have
hypothized that a high vitamin D serum levels might re-
sult in a lower antibody response to influenza infectionand vaccination [10-12]. However, this was not con-
firmed in a recent trial on vaccinated children that were
supplemented with 1000 IU of vitamin D [13]. The dif-
ferences within the influenza subgroups observed in our
cohort may be generated simply by chance, because the
investigated numbers in the subgroups were low.
When we investigated the association of vitamin D
with severity, we found that lower 1,25-OH but not
25-OH levels were significantly associated with increased
CURB score. For 25-OH, we detected only a non-
significant trend. A recent study on 272 Dutch CAP pa-
tients identified 25-OH deficiency (same cut off as in
our study) as independent predictor for ICU admission
Table 2 Impact of the presence of co-morbidity according to organ on 1,25-OH2 and 25-OH serum concentrations
(transformed age and season adjusted values, bold numbers represent significant differences)
Co-morbidity 1,25-OH in pg/ml Statistics 25-OH in ng/ml Statistics
n Mean SD p value Mean SD p value
Respiratory No 199 50.7 32.3 F1,296 = 1.41 14.6 8.6 F1,296 = 4.70
Yes 99 45.8 23.0 0.2356 12.6 8.3 0.0310
Hepatic No 288 49.6 29.5 F1,297 = 2.09 14.1 8.5 F1,297 = 4.84
Yes 11 37.2 27.9 0.1494 8.9 5.2 0.0285
Renal No 279 50.2 29.7 F1,297 = 10.63 14.0 8.6 F1,297 = 1.81
Yes 20 34.1 21.9 0.0012 12.7 7.7 0.1792
Diabetes mellitus No 256 49.1 30.0 F1,297 = 0.41 14.1 8.8 F1,297 = 0.28
Yes 43 48.9 27.2 0.5203 13.0 6.4 0.5945
Cardiac No 260 49.9 30.1 F1,296 = 2.50 14.1 8.7 F1,296 = 1.41
Yes 38 44.1 25.2 0.1151 13.2 6.8 0.2364
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for impact of age and season nor measure 1,25-OH2
[14]. Controlling for season is of major importance,
since most cases of CAP occur during winter, when
vitamin D levels, particularly 25-OH, are lower in the
general population. In that study, 53% of patients ex-
hibited deficiency compared to 82% in our study. The
180 days mortality was similar with 5.8% (our study
4.3%).
In our study, low 1,25-OH was significantly associated
with renal co-morbidity but not hepatic co-morbidity,
whereas low D 25-OH levels were significantly associated
with hepatic and pulmonary but not renal-comorbidity.
All these statistically significant associations can be
explained by the vitamin D metabolism: the 25-hy-
droxylation occurs in the liver and the consecutive
1-hydroxylation in the kidney. Obviously, low 25-OH
levels can be compensated for by increased renal hydro-
xylation. Vice versa, sufficient 25-OH levels do not neces-
sarily translate into sufficient 1,25-OH2 levels. The latter
is supported by the admittedly significant but non-marked
correlation between those two metabolites.
Altogether, this may provide a possible explanation for
the contradictory results of interventional studies on
supplementation if vitamin D. Obviously, supplementa-
tion of vitamin D is of minor benefit, if it cannot be
transformed into 1,25-OH2. This may explain that sup-
plementation may prevent respiratory tract infections in
otherwise healthy children [6] but not in elderly adults
with co-morbidities [15], and it may also add expla-
nation for the well-known association between renal co-
morbidity and pneumococcal disease [7].
Similar to us, a recent study in septic patients found no
significant difference for 25-OH but for 1,25-OH2 blood
levels between survivors and non-survivors at baseline.
They describe that for the same level of 25-OH, 1,25-OH2
would be lower in non-survivors compared to survivors[16]. The authors measured also the 24-hydroxylase
activity and concluded that the decreased 1,25-OH in the
non-survivors points to a decreased production and not
to increased degradation.
Therefore, to measure only the reservoir form (25-
OH) -as recommended by guidelines to determine the
vitamin D “status”- maybe insufficient. Effects of vitamin
D are primarily conferred by the active form (1,25-OH2)
and there is no linear relationship between the serum
levels of these 2 metabolites. In line with our approach,
Powe et al. stressed the importance of studying not only
25-OH but also 1,25-OH2 to understand the complex
effects of vitamin D metabolism in a recent study pub-
lished in the New England Journal of Medicine [17,18].
As a consequence, supplementation of 1,25-OH instead
of vitamin D may be more appropriate to exploit potential
protective effects of vitamin D, particularly in elderly per-
sons with co-morbidities, who exhibit an increased risk
for pneumonia. While animal sepsis models investigating
1,25-OH2 administration have shown promise, there is no
human randomized clinical trial [19-21]. Supplementation
with 1,25-OH2 is already the standard of care for patients
depending on hemodialysis to prevent osteoporosis and
hyperparathyroidism. However, 1,25-OH2 imposes a
greater risk for toxicity and demandable clinical trials
would therefore need a thorough monitoring of 1,25-OH2
levels.
Conclusion
According to our results, the link between vitamin D de-
ficiency and increased susceptibility to respiratory tract
infections is rather conferred by the decreased levels of
the activated form (1,25-OH2) than by decreased levels
of the vitamin D reservoir form (25-OH), that is natu-
rally lower in the winter-pneumonia season. Using trans-
formed data of 25-OH and 1,25-OH2 to effectively
control for age and season, we found a significant and
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levels and pneumonia severity, which could not be
detected for 25-OH. Our findings may explain, why vita-
min D supplementation targeting to normalize 25-OH
levels alone in a cohort with decreased capacity (e.g. be-
cause of age and co-morbidities) for activation of vita-
min D may not be sufficient to exploit the suspected
protective effects.
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